KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) FCF Margin (2016 - 2025)

Historic FCF Margin for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 150.16%.

  • Novavax's FCF Margin rose 3231400.0% to 150.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.37%, marking a year-over-year decrease of 258400.0%. This contributed to the annual value of 14.71% for FY2024, which is 633300.0% up from last year.
  • As of Q3 2025, Novavax's FCF Margin stood at 150.16%, which was up 3231400.0% from 73.0% recorded in Q2 2025.
  • Novavax's 5-year FCF Margin high stood at 150.16% for Q3 2025, and its period low was 426.67% during Q1 2023.
  • Its 5-year average for FCF Margin is 59.63%, with a median of 42.15% in 2023.
  • As far as peak fluctuations go, Novavax's FCF Margin soared by 8332200bps in 2021, and later crashed by -4117100bps in 2023.
  • Over the past 5 years, Novavax's FCF Margin (Quarter) stood at 160.12% in 2021, then soared by 75bps to 39.41% in 2022, then tumbled by -62bps to 63.71% in 2023, then plummeted by -211bps to 198.31% in 2024, then surged by 176bps to 150.16% in 2025.
  • Its last three reported values are 150.16% in Q3 2025, 73.0% for Q2 2025, and 28.01% during Q1 2025.